Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315). 18. September 2021 Griesinger F., Sebastian M., Brückl W., Hummel H.-D., Jaeschke B., Kern J., Wesseler C., Jänicke M., Fleitz A., Zacharias S., Hipper A., Groth A., Weichert W., Dörfel S., Petersen V., Schröder J., Wilke J., Eberhardt W.E.E., Thomas M., 2021. Annals of Oncology, Volume 32, Supplement 5, 2021, Pages S1015-S1016. https://doi.org/10.1016/j.annonc.2021.08.1926 Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria Bartsch R., Lüftner D., Balic M., Rinnerthaler G., Jackisch C., Müller V., Schmidt M., Harbeck N. Download… Weiterlesen Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients. Gröschel, A., Passlick, B., Stuschke, M., Christopoulos, P., Reck, M., Grah, C., Growth, A., Hipper, A., Chiabudini, M., Fleitz, A., Jänicke, M., Spring, L., Christoph,… Weiterlesen